Amriya Pharmaceutical Industries

What Amriya Pharmaceutical Industries does

Amriya Pharmaceutical Industries is a privately held Egyptian manufacturer of generic pharmaceutical products, founded in 1984 and operating as a member of Pharco Corporation, an Egyptian pharmaceutical conglomerate. The company develops and manufactures generics across an unusually broad set of dosage forms — tablets, capsules, suppositories, syrups, lotions, suspensions, creams, ointments, vials, ampoules, and drops — targeting the Egyptian healthcare market (providers and patients requiring affordable generic medications). Its stated mission is to deliver "the highest quality, most effective pharmaceutical products," with stated commitments to controlled growth, talent retention, and sustained expertise development.

The company's revenue model is straightforward generic-pharmaceutical product sales, with no licensing, subscription, or platform economics disclosed; pricing is not publicly disclosed. Its competitive positioning rests on multi-dosage-form manufacturing breadth and on its affiliation with the larger Pharco group, which provides implied access to group-level commercial and distribution infrastructure. Distribution channels, end-market segmentation, certifications, and contract relationships are not detailed in publicly available material, and the company's own website exposes only a sparse homepage (with most product, quality, R&D, and contact pages returning 404), which limits external visibility into operational depth.

Information on headcount, plant capacity, regulatory approvals, export markets, named customers, management team, M&A activity, and financial performance is not present in the source data. The operating status is described as active, and the company is recognized as a Pharco group entity, but specific strategic actions beyond the 1984 founding and group membership are not documented.

Name

Amriya Pharmaceutical Industries

Legal name

Amriya Pharmaceutical Industries

Website

https://amriyapharm.com

Company type

Private

Founded year

1984

Operating status

Operating

Short description

Amriya Pharmaceutical Industries is an Egyptian generic pharmaceutical manufacturer, founded in 1984 and operating as a member of Pharco Corporation. It produces generics in tablets, capsules, suppositories, syrups, lotions, suspensions, creams, ointments, vials, ampoules, and drops for the healthcare market.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Multiple dosage forms
• Drug formulations
• Generic medications

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: Development and manufacturing of generic pharmaceutical products across multiple dosage forms including tablets, capsules, suppositories, syrups, lotions, suspension, creams, ointments, vials, ampoules and drops

Core offering

Amriya Pharmaceutical Industries develops and manufactures generic pharmaceutical products across multiple dosage forms including tablets, capsules, suppositories, syrups, lotions, suspensions, creams, ointments, vials, ampoules, and drops. Established in 1984, the company focuses on producing high-quality, effective generic medications for the healthcare market as a member of Pharco Corporation.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Pharmaceuticals Portfolio Comprehensive portfolio of generic pharmaceutical products manufactured across multiple dosage forms including tablets, capsules, suppositories, syrups, lotions, suspensions, creams, ointments, vials, ampoules, and drops. Targeted at the healthcare market for use by healthcare providers and patients requiring high-quality, effective generic medications.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Pharco CorporationcoreStrategic or Co-development PartnerAmriya Pharmaceutical Industries is a member of Pharco Corporation, indicating a corporate membership/affiliation within a larger pharmaceutical group. The relationship appears to be that Amriya is part of the Pharco corporate family.

Scale indicators2 records

Recent moves1 record

Expansion highlights2 records

Direct peers

• EIPICO (Egyptian International Pharmaceutical Industries Company): One of Egypt's largest generic pharmaceutical manufacturers producing a wide range of finished dosage forms. EIPICO is the most direct domestic competitor to Amriya, competing for the same Egyptian institutional and retail customers across overlapping therapeutic categories.
• Eva Pharma: Major Egyptian pharmaceutical manufacturer with a broad generics portfolio spanning multiple dosage forms and therapeutic areas. Eva Pharma competes head-to-head with Amriya in the Egyptian generics market and increasingly across regional export channels.
• Minapharm Pharmaceuticals: Egypt-based pharmaceutical manufacturer specializing in generics and biopharmaceuticals with multi-dosage form production. Minapharm is a directly comparable peer with overlapping domestic market positioning and a similar mix of generic finished dosage forms.
• Mepaco Pharmaceutical Company: Egyptian pharmaceutical manufacturer operating within the Pharco corporate family, producing generics across multiple dosage forms. As a sister company, Mepaco shares similar capabilities and customer base, making it the closest internal comparable for Amriya.

Broad incumbents

• Pharco Pharmaceuticals: The parent corporate group of Amriya and Egypt's largest pharmaceutical company by sales. Pharco is a broad incumbent operating the full value chain across branded, generic, and biotech products, making it the principal internal benchmark for Amriya's positioning.
• Hikma Pharmaceuticals: A leading MENA-headquartered multinational pharmaceutical company with a strong generics and specialty portfolio. Hikma overlaps with Amriya in generics manufacturing and regional distribution, providing a public-market benchmark for valuation and operational scale.
• Cipla: Global Indian generic pharmaceutical major with significant presence across emerging markets including MENA. Comparable as a broad generic finished dosage form manufacturer competing for institutional tenders and export contracts in similar therapeutic categories.

Regional players

• Julphar (Gulf Pharmaceutical Industries): One of the largest pharmaceutical manufacturers in the MENA region, producing generics across tablets, injectables, syrups, and other dosage forms. Julphar is comparable as a regional MENA generics competitor targeting similar institutional customers across overlapping therapeutic categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amriya Pharmaceutical Industries